Abstract:BACKGROUND: The spared nerve injury (SNI) model is a new animal model that can mimic several characteristics of clinical neuropathic pain. Opioids are recommended as treatment of neuropathic pain. Therefore, the present study was conducted to investigate the antinociceptive effects of endomorphin-1 (EM-1) and endomorphin-2 (EM-2) given centrally and peripherally in the SNI model of neuropathic pain in mice. METHODS: The SNI model was made in mice by sparing the sural nerve intact, when the other 2 of 3 terminal branches of the sciatic nerve (common peroneal and tibial nerves) were tightly ligated and cut. Von Frey monofilaments were used to measure the SNI-induced mechanical allodynia-like behavior. The antiallodynic effects of EM-1 and EM-2 were determined after central and peripheral administration in the SNI model of neuropathic pain. Also, the specific opioid receptor antagonists were used to determine the opioid mechanisms of EMs involved in neuropathic pain. Values were expressed as the mean ± standard deviation. RESULTS: Our results showed that the SNI mice developed prolonged mechanical allodynia-like behavior in ipsilateral paw after surgery, with the withdrawal threshold value being 0.061 ± 0.02 g after 14 days. EM-1 and EM-2 produced significant antiallodynic effects in ipsilateral paw after intracerebroventricular (i.c.v.) administration, more effective than that of morphine. The peak withdrawal thresholds of 10 nmol EM-1 and EM-2 determined at 5 minutes after injection were 0.92 ± 0.36 and 0.87 ± 0.33 g, respectively, higher than that of morphine (0.46 ± 0.20 g). Moreover, both EMs (10 nmol, i.c.v.) exerted significant antiallodynic effects in the contralateral paw, whereas no significant antinociceptive activity was seen after i.c.v. administration of morphine with equimolar dose. It was noteworthy that EM-1 and EM-2 produced antinociception through distinct μ1- and μ2-opioid receptor subtypes, and the EM-2-induced antiallodynia contained an additional component that was mediated by the release of endogenous dynorphin A, acting on κ-opioid receptor. In addition, the antiallodynic activities of peripheral administration of EM-1, EM-2, and morphine were also investigated. Intraplantar, but not subcutaneous administration of EM-1 and EM-2 also exhibited potent antinociception, establishing the peripheral and local effects. Both μ1- and μ2-opioid receptor subtypes, but not the δ- or κ-opioid receptors were involved in the peripheral antiallodynia of EMs. CONCLUSIONS: The present investigation demonstrated that both EM-1 and EM-2 given centrally and peripherally produced potent antiallodynic activities in SNI mice, and differential opioid mechanisms were involved.

Endomorphin-1 Analogs with Oligoarginine-Conjugation at C-terminus Produce Potent Antinociception with Reduced Opioid Tolerance in Paw Withdrawal Test.

Endomorphin-2 Analogs with C-terminal Esterification Produce Potent Systemic Antinociception with Reduced Tolerance and Gastrointestinal Side Effects

Synthesis and Antinociceptive Effects of Endomorphin-1 Analogs with C-terminal Linked by Oligoarginine

Novel endomorphin-1 analogs with C-terminal oligoarginine-conjugation display systemic antinociceptive activity with less gastrointestinal side effects.

Novel Cyclic Endomorphin Analogues with Multiple Modifications and Oligoarginine Vector Exhibit Potent Antinociception with Reduced Opioid-like Side Effects

Novel endomorphin analogs CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favorable side effect profile at the spinal level

Endomorphin-2 Analogs with C-terminal Esterification Display Potent Antinociceptive Effects in the Formalin Pain Test in Mice.

Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics

Novel Endomorphin Analogues CEMR-1 and CEMR-2 Produce Potent and Long-Lasting Antinociception with a Favourable Side Effect Profile at the Spinal Level

C-terminal Hydrazide Modification Changes the Spinal Antinociceptive Profiles of Endomorphins in Mice.

In Vitro and in Vivo Characterization of Opioid Activities of C-terminal Esterified Endomorphin-2 Analogs

Differential Antinociceptive Effects of Intrathecal Administration of C‐terminal Esterified Endomorphin‐2 Analogues in Mice

Novel chimeric peptides based on endomorphins and ghrelin receptor antagonist produced supraspinal antinociceptive effects with reduced acute tolerance in mice

Characterization of Opioid Activities of Endomorphin Analogs with C-Terminal Amide to Hydrazide Conversion

The spinal anti-allodynic effects of endomorphin analogs with C-terminal hydrazide modification in neuropathic pain model

Synthesis and Biological Evaluations of Novel Endomorphin Analogues Containing Α-Hydroxy-β-phenylalanine (AHPBA) Displaying Mixed Μ/δ Opioid Receptor Agonist and Δ Opioid Receptor Antagonist Activities.

In vitro and in vivo characterization of opioid activities of endomorphins analogs with novel constrained C-terminus: evidence for the important role of proper spatial disposition of the third aromatic ring.

Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice

MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile

Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord

Antiallodynic Effects of Endomorphin-1 and Endomorphin-2 in the Spared Nerve Injury Model of Neuropathic Pain in Mice